SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Gilead Sciences

116

Gilead Sciences

GILD

California-based Gilead is a biopharmaceutical firm best known for its hepatitis C cures Sovaldi and Harvoni.

Looking for leads, investment insights, or competitive intelligence?

CEO

John F. Milligan IV

CEO Title

President, Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Foster City, Calif.

Years on Fortune 500 List

10

Employees

10,000

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$26,107-14.1%
Profits ($M)$4,628.0-65.7%
Assets ($M)$70,283
Total Stockholder Equity ($M)$20,442
Market Value — as of March 29, 2018 ($M)$98,298
Profit Ratios
Profit as % of Revenues17.7%
Profits as % of Assets6.6%
Profits as % of Stockholder Equity22.6%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)3.51
EPS % Change (from 2016)-64.7%
EPS % Change (5 year annual rate)16.4%
EPS % Change (10 year annual rate)15.4%
Total Return
Total Return to Investors (2017)2.9%
Total Return to Investors (5 year, annualized)15.8%
Total Return to Investors (10 year, annualized)12.7%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

The blockbuster public offering pegs Allogene's market value at more than $2 billion.

Read More →
The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs

Celgene and Novartis are among the companies accused of thwarting generic drugs.

Read More →
Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race

On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.

Read More →